Please select the option that best describes you:

How do you counsel patients with metastatic NSCLC who have a sustained response (> 2 years) to checkpoint inhibitors who wish to discontinue therapy?   

How do you approach this given the limited # of patients this applies to?  Checkmate 017 and 057 only had 5-7% of patients still on nivolumab at 3 years and in Keynote 010 with similar % of patients completing 2 years of therapy.



Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at NYU Winthrop Hospital
If immunotherapy is paid by insurance and there ar...
Medical Oncologist at Kaiser Permanente
I would appreciate sharing of the citations for da...
Medical Oncologist at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
This is one reference.Also look at this uptodate s...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more